Abstract B047: CXCR4 synergizes with multi-RAS inhibition by overcoming T cell exclusion to enhance immunogenic cancer cell death in human pancreatic cancer slice culture
The multi-RAS inhibitor, daraxonrasib, has demonstrated a remarkable improvement in outcomes for patients with metastatic PDAC. Pre-clinical murine studies have shown that the durable effects of the pre-clinical multi-RAS inhibitor, RMC-7977, require an intact immune system including CD8+ T cells and cross-presen...